Angelini to Buy Catalyst Pharmaceuticals for $4.1 Billion at 70% Premium
Angelini Pharma will acquire Catalyst Pharmaceuticals in an all-cash transaction valued at $4.1 billion, representing roughly a 70% premium to Catalyst’s closing share price. The deal is expected to close in the second half of 2026 pending regulatory clearances and shareholder approval.
1. Deal Structure and Valuation
Angelini Pharma agreed to purchase all outstanding Catalyst Pharmaceuticals shares for $4.1 billion in cash, valuing the company at an approximately 70% premium to its last closing share price. The implied per-share consideration was set to deliver immediate value to Catalyst investors.
2. Strategic Rationale
The acquisition will bolster Angelini’s presence in the rare-disease specialty pharma sector by adding Catalyst’s commercial and late-stage assets to its portfolio. Catalyst’s pipeline and marketed products are expected to complement Angelini’s existing neuromuscular and orphan-disease franchises.
3. Closing Timeline and Requirements
The transaction is slated to close in the second half of 2026, subject to customary regulatory approvals and a vote by Catalyst Pharmaceuticals’ shareholders. Angelini plans to fund the deal through a combination of debt financing and existing cash resources.